/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice
S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

OncLive® On Air · Sep 28, 2026

Experts discuss NGS-guided therapy for HR+/HER2- MBC post-CDK4/6i, weighing capivasertib, getatolisib, and oral SERDs for specific mutations.

Clinicians View the 12-Month Adjuvant AI Recurrence Rule as an Arbitrary Cutoff

Experts question the biological validity of the one-year cutoff for recurrence after adjuvant Aromatase Inhibitor (AI) therapy, a common clinical trial inclusion criterion. They suggest that clinical judgment should be applied, as the biological reality of resistance is not a binary switch at 12 months.

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice thumbnail

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

OncLive® On Air·2 months ago

mTOR Inhibitors Like Geta may be Superior to AKT Inhibitors for Tumors with PTEN Loss

Preclinical data suggests tumors with PTEN loss develop a heightened dependence on the mTOR pathway. This provides a strong biological rationale for selecting an mTOR inhibitor, like getatolisib, over an AKT or PI3K inhibitor in this specific patient subpopulation for potentially better efficacy.

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice thumbnail

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

OncLive® On Air·2 months ago

TP53 Mutation Is a Key Marker Justifying More Aggressive Combination Therapy

Beyond specific pathway alterations like ESR1 or PIK3CA, clinicians view a concurrent TP53 mutation as a robust marker of aggressive disease biology. This common finding is used to justify choosing more aggressive combination therapies over potentially less effective single-agent approaches.

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice thumbnail

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

OncLive® On Air·2 months ago

Oncologists Use Serial ctDNA Monitoring to Preempt Radiographic Progression in Aggressive Cancers

For patients with aggressive, rapidly progressing disease, clinicians use serial ctDNA monitoring between scheduled imaging scans. A rising ctDNA tumor fraction can serve as an early warning sign of treatment failure, allowing for quicker therapeutic pivots before the cancer grows significantly.

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice thumbnail

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

OncLive® On Air·2 months ago

Re-Challenging with PI3K/mTOR Inhibitor Is More Logical After PI3K Than AKT Inhibitor Failure

Experts theorize that because resistance to PI3K inhibitors often involves downstream AKT activation, subsequent use of an AKT inhibitor is logical. However, re-challenging the pathway with a PI3K/mTOR agent like getatolisib after an AKT inhibitor has already failed is seen as less rational based on pathway biology.

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice thumbnail

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

OncLive® On Air·2 months ago

Advocates Urge Tissue Biopsy to Confirm Negative Liquid Biopsy in Patients with Liver Metastases

In patients with liver metastases, a low tumor fraction can cause false-negative liquid biopsy (ctDNA) results. Clinicians recommend obtaining a tissue biopsy to confirm the absence of targetable mutations and ensure concordance, preventing misinformed treatment decisions based on potentially inaccurate ctDNA.

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice thumbnail

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

OncLive® On Air·2 months ago

Slow 'Grumbling' Disease Progression Justifies Extended CDK4/6 Inhibitor Use

When a patient exhibits slow, indolent ('grumbling') progression on a first-line CDK4/6 inhibitor, clinicians may opt to continue with a different CDK4/6 inhibitor combined with fulvestrant. This strategy prioritizes quality of life and defers more toxic or novel therapies for later lines.

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice thumbnail

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

OncLive® On Air·2 months ago

Oncology May Shift to Proactive Treatment Changes Based on Pre-Progression Biomarker Detection

Experts are enthusiastic about a future paradigm where treatment is adjusted based on detecting emerging resistance mutations (like ESR1) via liquid biopsy before clinical progression occurs. This proactive approach aims to target small resistance clones early, potentially improving long-term outcomes.

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice thumbnail

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

OncLive® On Air·2 months ago